Structure-Guided Designed [18F]-labeled FAPI for Enhanced Hydrophilicity: From Preclinical to First-In-Human Study
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.5c03486 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Xingyu Mu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin 541001, China. Hauptthemen laut MEDLINE: Fibroblast Activation Protein Alpha, Fluorine Radioisotopes, Gelatinases, Radiopharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Guangxi Zhuang Autonomous Region Health and Family Planning Commission, Morningside Foundation, Natural Science Foundation of Guangxi Zhuang Autonomous Region.
Abstract (Originalsprache)
Fibroblast activation protein (FAP) is highly expressed in cancer-associated fibroblasts and represents an attractive target for PET imaging. Here, we report [18F]AlF-NOTA-GL01, an improved FAPI-46 derivative bearing an N-methyl-benzenesulfonic acid side chain and labeled via an Al[18F]-NOTA platform. [18F]AlF-NOTA-GL01 was obtained with high radiochemical purity (>95%), high FAP binding affinity (IC50 = 2.94 nM), and high hydrophilicity (LogD = −3.06). In A549-hFAP xenografts, PET imaging showed high tumor uptake (7.45 ± 2.34%ID/g at 60 min), rapid renal clearance, and low hepatobiliary background, with strong concordance between PET-derived uptake and ex vivo biodistribution. In a first-in-human study, physiologic uptake decreased over time, whereas tumor uptake persisted to 120 min. The effective dose was 0.03 ± 0.01 mSv/MBq. Malignant lesions exhibited higher target-to-background ratios on [18F]AlF-NOTA-GL01 PET/CT than on [18F]FDG and [18F]FAPI-42. Collectively, these findings support the clinical translation potential of [18F]AlF-NOTA-GL01, which combines high affinity with excellent imaging contrast.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, The First Affiliated Hospital of Guilin Medical University, Guilin 541001, China.
- Guilin Translational Science and Technology Innovation Center for Nuclear Medicine and Molecular Imaging, The First Affiliated Hospital of Guilin Medical University, Guilin 541001, China.
- Key Laboratory Project of Guangdong Provincial Department of Education for Ordinary Universities and GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Department of Nuclear Medicine, Nanfa…
- School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, Guangdong 510515, China.
- Serilink Biotechnology Company Limited, Hong Kong 999077, China.
- Department of Chemistry, State Key Laboratory of Synthetic Chemistry, The University of Hong Kong, Hong Kong 999077, China.
ORCID-Profile: Ganghua Tang, Xuechen Li, Wei Fu
Förderung
- Guangxi Zhuang Autonomous Region Health and Family Planning Commission
- Morningside Foundation
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
- National Natural Science Foundation of China
Zitieren
APA
Mu, X., Zhang, L., Chen, Z., Chow, H. Y., Li, J., Chong, W., Mo, Y., Tang, G., Li, X., & Fu, W. (2026). Structure-Guided Designed [18F]-labeled FAPI for Enhanced Hydrophilicity: From Preclinical to First-In-Human Study. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c03486
Vancouver
Mu X, Zhang L, Chen Z, Chow HY, Li J, Chong W, et al. Structure-Guided Designed [18F]-labeled FAPI for Enhanced Hydrophilicity: From Preclinical to First-In-Human Study. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.5c03486
BibTeX
@article{Mu2026,
author = {Mu, Xingyu and Zhang, Lei and Chen, Zihao and Chow, Hoi Yee and Li, Jingze and Chong, Weixia and Mo, Yufeng and Tang, Ganghua and Li, Xuechen and Fu, Wei},
title = {Structure-Guided Designed [18F]-labeled FAPI for Enhanced Hydrophilicity: From Preclinical to First-In-Human Study},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.5c03486}
}
EUVIMED